113 related articles for article (PubMed ID: 32693686)
1. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
2. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C
J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194
[TBL] [Abstract][Full Text] [Related]
3. A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas.
Lippai Z; Péterfia B; Papp G; Dezső K; Bedics G; Pápai Z; Lamers MH; Kuin RC; Szuhai K; Sápi Z
Eur J Cancer; 2024 May; 202():114005. PubMed ID: 38531265
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
5. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
Laetsch TW
Clin Adv Hematol Oncol; 2024 May; 22 Suppl 3(4):1-11. PubMed ID: 38739704
[No Abstract] [Full Text] [Related]
6. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
7. Primary NTRK -rearranged Spindle Cell Neoplasm of the Gastrointestinal Tract: A Clinicopathological and Molecular Analysis of 8 Cases.
Gao X; Xu S; Zhu P; Lao IW; Yu L; Wang J
Am J Surg Pathol; 2024 May; 48(5):623-631. PubMed ID: 38525823
[TBL] [Abstract][Full Text] [Related]
8. Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology.
Vince CSC; Brassesco MS; Mançano BM; Gregianin LJ; Carbone EK; do Amaral E Castro A; Dwan VSY; Menezes da Silva RZ; Mariano CS; da Mata JF; Silva MO; Caran EMM; Macedo CD; Alves da Costa G; Esteves TC; Silva LN; Ferman SE; Martins FD; Cristófani LM; Odone-Filho V; Silva MM; Reis RM; Pianovski MAD; Campregher PV; Kunii MS; de Sá Rodrigues KE; Carvalho Filho NP; Valera ET;
JCO Precis Oncol; 2024 May; 8():e2300713. PubMed ID: 38810175
[TBL] [Abstract][Full Text] [Related]
9. NTRK-rearranged spindle cell sarcoma of the uterine cervix with a novel NUMA1::NTRK1 fusion.
Szalai L; Vereczkey I; Szemes M; Rókusz A; Csernák E; Tóth E; Melegh Z
Virchows Arch; 2024 Mar; 484(3):527-531. PubMed ID: 38151535
[TBL] [Abstract][Full Text] [Related]
10. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
Bokemeyer C; Paracha N; Lassen U; Italiano A; Sullivan SD; Marian M; Brega N; Garcia-Foncillas J
JCO Precis Oncol; 2023 Jan; 7():e2200436. PubMed ID: 36689698
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).
Orbach D; Carton M; Khadir SK; Feuilly M; Kurtinecz M; Phil D; Vokuhl C; Koscielniak E; Pierron G; Lemelle L; Sparber-Sauer M
ESMO Open; 2024 May; 9(5):103006. PubMed ID: 38657345
[TBL] [Abstract][Full Text] [Related]
12. Response to Repotrectinib After Development of
Chen MF; Yang SR; Shia J; Girshman J; Punn S; Wilhelm C; Kris MG; Cocco E; Drilon A; Raj N
JCO Precis Oncol; 2023 May; 7():e2200697. PubMed ID: 37262390
[No Abstract] [Full Text] [Related]
13. [NTRK-rearranged uterine sarcoma: a clinicopathological analysis of seven cases].
Huang HJ; Wang C; Fan DG; He YH; Chen X; Zheng SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):189-191. PubMed ID: 38281791
[No Abstract] [Full Text] [Related]
14. Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report.
Percy C; Schubert T; Galant C; Kirchgesner T; Mazzeo F
Clin Case Rep; 2021 Mar; 9(3):1694-1698. PubMed ID: 33768917
[TBL] [Abstract][Full Text] [Related]
15. Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors.
Rosen EY; Schram AM; Young RJ; Schreyer MW; Hechtman JF; Shu CA; Ku NC; Hyman DM; Drilon A
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914009
[No Abstract] [Full Text] [Related]
16. Marked effect of larotrectinib on primary cutaneous secretory carcinoma: A case report.
Hayakawa K; Irisawa R; Umefune R; Mae K; Shimada Y; Takahashi R; Nagao T; Harada K
J Dermatol; 2024 Apr; ():. PubMed ID: 38605458
[No Abstract] [Full Text] [Related]
17. Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer.
Groussin L; Clerc J; Huillard O
N Engl J Med; 2020 Oct; 383(17):1686-1687. PubMed ID: 33085869
[No Abstract] [Full Text] [Related]
18. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST).
Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144
[TBL] [Abstract][Full Text] [Related]
19. NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.
Dahl NA; Donson AM; Sanford B; Wang D; Walker FM; Gilani A; Foreman NK; Tinkle CL; Baker SJ; Hoffman LM; Venkataraman S; Vibhakar R
J Neuropathol Exp Neurol; 2021 Mar; 80(4):345-353. PubMed ID: 33749791
[TBL] [Abstract][Full Text] [Related]
20. Comment on: A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Slomovic A; Amaral T; Lobko I; Siegel DN; Goldfisher R; Kessel R; Levy CF
Pediatr Blood Cancer; 2021 Jun; 68(6):e28953. PubMed ID: 33694317
[No Abstract] [Full Text] [Related]
[Next] [New Search]
